NRC-2694 is an epidermal growth factor receptor (EGFR) antagonist with anti-cancer and anti-proliferative properties.

NRC-2694 at 80 ng (190 nm) concentrations causes comparable inhibition of EGFR expression^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

In toxicity studies, the maximum tolerated dose of NRC-2694 in male and female mice is 2000 mg/kg (po). NRC-2694 (10 mg/kg) regresses the tumor in mice^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

418.49

C₂₄H₂₆N₄O₃

936446-61-6

Room temperature in continental US; may vary elsewhere.

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

In Vitro: 

DMSO : 250 mg/mL (597.39 mM; Need ultrasonic)

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

  Solubility: ≥ 2.08 mg/mL (4.97 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (4.97 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

  Solubility: ≥ 2.08 mg/mL (4.97 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (4.97 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 3.

  请依序添加每种溶剂： 10% DMSO    90% corn oil

  Solubility: ≥ 2.08 mg/mL (4.97 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (4.97 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

• [1]. Ramanadham Jyothi Prasad, et al. 6-7,dialkoxy quinazoline derivatives useful for treatment of cancer related disorders. US 8143250 B2

The in vitro invasiveness of H1299 and A549 cells in the presence of various concentrations of NRC compounds (as determined by MTT assay) is assessed using a modified Boyden chamber assay. Cells are treated with these compounds for 48 hr. 1×10⁶ cells are suspended in 600 μL of serum-free medium supplemented with 0.2% BSA and placed in the upper compartment of the transwell chambers coated with matrigel (0.7 mg/mL). The lower compartment of the chamber is filled with 200 μL of serum medium and the cells are allowed to migrate for 24 h. after incubation, the cells are fixed and stained with Hema-3 and quantified. The migrated cells are quantified as percent invasion.

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Mice: Nude mice are implanted with 2×10⁶ A549 cells in the right hind limb flank. Upon the observance of a tumour (>2 mm), mice are given oral or ip treatments of the test compounds including erlotinib HCl used as positive control. A dose of 100 mg/kg of erlotinib HCl is identified as the base line dose.

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Ramanadham Jyothi Prasad, et al. 6-7,dialkoxy quinazoline derivatives useful for treatment of cancer related disorders. US 8143250 B2